Molecular Weight:   | 179.09 |
Volume:   | 190.991 |
LogP:   | 2.404 |
LogD:   | 1.073 |
LogS:   | -2.446 |
# Rotatable Bonds:   | 4 |
TPSA:   | 50.19 |
# H-Bond Aceptor:   | 3 |
# H-Bond Donor:   | 1 |
# Rings:   | 1 |
# Heavy Atoms:   | 3 |
QED Drug-Likeness Score:   | 0.77 |
Synthetic Accessibility Score:   | 1.828 |
Fsp3:   | 0.4 |
Lipinski Rule-of-5:   | Accepted |
Pfizer Rule:   | Accepted |
GSK Rule:   | Accepted |
BMS Rule:   | 0 |
Golden Triangle Rule:   | Rejected |
Chelating Alert:   | 1 |
PAINS Alert:   | 0 |
Caco-2 Permeability:   | -4.638 |
MDCK Permeability:   | 2.2023989004082978e-05 |
Pgp-inhibitor:   | 0.001 |
Pgp-substrate:   | 0.001 |
Human Intestinal Absorption (HIA):   | 0.004 |
20% Bioavailability (F20%):   | 0.003 |
30% Bioavailability (F30%):   | 0.333 |
Blood-Brain-Barrier Penetration (BBB):   | 0.293 |
Plasma Protein Binding (PPB):   | 79.25231170654297% |
Volume Distribution (VD):   | 0.35 |
Pgp-substrate:   | 19.732969284057617% |
CYP1A2-inhibitor:   | 0.162 |
CYP1A2-substrate:   | 0.136 |
CYP2C19-inhibitor:   | 0.079 |
CYP2C19-substrate:   | 0.06 |
CYP2C9-inhibitor:   | 0.088 |
CYP2C9-substrate:   | 0.315 |
CYP2D6-inhibitor:   | 0.021 |
CYP2D6-substrate:   | 0.124 |
CYP3A4-inhibitor:   | 0.02 |
CYP3A4-substrate:   | 0.06 |
Clearance (CL):   | 1.581 |
Half-life (T1/2):   | 0.702 |
hERG Blockers:   | 0.126 |
Human Hepatotoxicity (H-HT):   | 0.427 |
Drug-inuced Liver Injury (DILI):   | 0.965 |
AMES Toxicity:   | 0.003 |
Rat Oral Acute Toxicity:   | 0.925 |
Maximum Recommended Daily Dose:   | 0.027 |
Skin Sensitization:   | 0.156 |
Carcinogencity:   | 0.055 |
Eye Corrosion:   | 0.013 |
Eye Irritation:   | 0.966 |
Respiratory Toxicity:   | 0.839 |
Natural Product ID:   | NPC41717 |
Common Name*:   | Fusaric Acid |
IUPAC Name:   | 5-butylpyridine-2-carboxylic acid |
Synonyms:   | 5-Butylpicolinic Acid; Fusaric Acid |
Standard InCHIKey:   | DGMPVYSXXIOGJY-UHFFFAOYSA-N |
Standard InCHI:   | InChI=1S/C10H13NO2/c1-2-3-4-8-5-6-9(10(12)13)11-7-8/h5-7H,2-4H2,1H3,(H,12,13) |
SMILES:   | CCCCc1ccc(C(=O)O)nc1 |
Synthetic Gene Cluster:   | BGC0001190; |
ChEMBL Identifier:   | CHEMBL24510 |
PubChem CID:   |
3442 |
Chemical Classification**:   |
|
*Note: the InCHIKey will be temporarily assigned as the "Common Name" if no IUPAC name or alternative short name is available.
**Note: the Chemical Classification was calculated by NPClassifier Version 1.5. Reference: PMID:34662515.
Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO24024 | Fusarium semitectum | Species | Nectriaceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[10978211] |
NPO24024 | Fusarium semitectum | Species | Nectriaceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[22439674] |
NPO41421 | Fusarium oxysporum + Sarocladium strictum | Species | n.a. | n.a. | n.a. | n.a. | n.a. |
PMID[26999098] |
NPO24024 | Fusarium semitectum | Species | Nectriaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO11278 | Scheffleropsis angkae | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | Database[UNPD] |
NPO12206 | Pterocaulon sphacelatum | Species | Asteraceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO8558 | Pseudognaphalium robustum | Species | Asteraceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO3889 | Streptomyces humidus | Species | Streptomycetaceae | Bacteria | n.a. | n.a. | n.a. | Database[UNPD] |
☑ Note for Reference:
In addition to directly collecting NP source organism data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated them from below databases:
☉ UNPD: Universal Natural Products Database [PMID: 23638153].
☉ StreptomeDB: a database of streptomycetes natural products [PMID: 33051671].
☉ TM-MC: a database of medicinal materials and chemical compounds in Northeast Asian traditional medicine [PMID: 26156871].
☉ TCM@Taiwan: a Traditional Chinese Medicine database [PMID: 21253603].
☉ TCMID: a Traditional Chinese Medicine database [PMID: 29106634].
☉ TCMSP: The traditional Chinese medicine systems pharmacology database and analysis platform [PMID: 24735618].
☉ HerDing: a herb recommendation system to treat diseases using genes and chemicals [PMID: 26980517].
☉ MetaboLights: a metabolomics database [PMID: 27010336].
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Organism ID | NP ID | Organism Material Preparation | Organism Part | NP Quantity (Standard) | NP Quantity (Minimum) | NP Quantity (Maximum) | Quantity Unit | Reference |
---|
☑ Note for Reference:
In addition to directly collecting NP quantitative data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated NP quantitative records for specific NP domains (e.g., NPS from foods or herbs) from domain-specific databases. These databases include:
☉ DUKE: Dr. Duke's Phytochemical and Ethnobotanical Databases.
☉ PHENOL EXPLORER: is the first comprehensive database on polyphenol content in foods [PMID: 24103452], its homepage can be accessed at here.
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT2805 | Individual Protein | Dopamine beta-hydroxylase | Bos taurus | Ki | = | 149.0 | nM | PMID[521190] |
NPT2806 | Individual Protein | Dopamine beta-hydroxylase | Rattus norvegicus | IC50 | = | 700.0 | nM | PMID[521191] |
NPT2807 | Individual Protein | Hypoxia-inducible factor prolyl 4-hydroxylase | Homo sapiens | IC50 | = | 149000.0 | nM | PMID[521192] |
NPT2805 | Individual Protein | Dopamine beta-hydroxylase | Bos taurus | Ki | = | 149.0 | nM | PMID[521193] |
NPT483 | Individual Protein | Prelamin-A/C | Homo sapiens | Potency | = | 7079.5 | nM | PMID[521198] |
NPT163 | Individual Protein | Nuclear factor NF-kappa-B p105 subunit | Homo sapiens | Potency | = | 3162.3 | nM | PMID[521199] |
NPT48 | Individual Protein | Lysine-specific demethylase 4D-like | Homo sapiens | Potency | = | 3981.1 | nM | PMID[521198] |
NPT48 | Individual Protein | Lysine-specific demethylase 4D-like | Homo sapiens | Potency | = | 10000.0 | nM | PMID[521200] |
NPT48 | Individual Protein | Lysine-specific demethylase 4D-like | Homo sapiens | Potency | = | 44668.4 | nM | PMID[521197] |
NPT210 | Individual Protein | Thyroid stimulating hormone receptor | Homo sapiens | Potency | = | 25118.9 | nM | PMID[521199] |
NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | = | 44668.4 | nM | PMID[521200] |
NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | = | 8912.5 | nM | PMID[521197] |
NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | = | 17782.8 | nM | PMID[521198] |
NPT51 | Individual Protein | Microtubule-associated protein tau | Homo sapiens | Potency | = | 7943.3 | nM | PMID[521200] |
NPT531 | Individual Protein | Nuclear receptor ROR-gamma | Mus musculus | Potency | = | 8912.5 | nM | PMID[521198] |
NPT531 | Individual Protein | Nuclear receptor ROR-gamma | Mus musculus | Potency | = | 25118.9 | nM | PMID[521200] |
NPT531 | Individual Protein | Nuclear receptor ROR-gamma | Mus musculus | Potency | = | 7079.5 | nM | PMID[521197] |
NPT211 | Individual Protein | Hypoxia-inducible factor 1 alpha | Homo sapiens | Potency | = | 2511.9 | nM | PMID[521198] |
NPT211 | Individual Protein | Hypoxia-inducible factor 1 alpha | Homo sapiens | Potency | = | 15848.9 | nM | PMID[521199] |
NPT53 | Individual Protein | 4'-phosphopantetheinyl transferase ffp | Bacillus subtilis | Potency | = | 39810.7 | nM | PMID[521198] |
NPT53 | Individual Protein | 4'-phosphopantetheinyl transferase ffp | Bacillus subtilis | Potency | = | 28183.8 | nM | PMID[521200] |
NPT52 | Individual Protein | Pyruvate kinase isozymes M1/M2 | Homo sapiens | Potency | = | 251.2 | nM | PMID[521199] |
NPT53 | Individual Protein | 4'-phosphopantetheinyl transferase ffp | Bacillus subtilis | Potency | = | 44668.4 | nM | PMID[521197] |
NPT54 | Individual Protein | Nonstructural protein 1 | Influenza A virus | Potency | = | 22387.2 | nM | PMID[521200] |
NPT55 | Individual Protein | Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | = | 9976.3 | nM | PMID[521198] |
NPT55 | Individual Protein | Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | = | 8891.4 | nM | PMID[521197] |
NPT55 | Individual Protein | Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | = | 15811.4 | nM | PMID[521200] |
NPT56 | Individual Protein | Beta-lactamase AmpC | Escherichia coli K-12 | Potency | = | 10000.0 | nM | PMID[521202] |
NPT58 | Individual Protein | Bloom syndrome protein | Homo sapiens | Potency | = | 3.2 | nM | PMID[521200] |
NPT531 | Individual Protein | Nuclear receptor ROR-gamma | Mus musculus | Potency | = | 7943.3 | nM | PMID[521198] |
NPT531 | Individual Protein | Nuclear receptor ROR-gamma | Mus musculus | Potency | = | 17782.8 | nM | PMID[521200] |
NPT109 | Individual Protein | Cytochrome P450 3A4 | Homo sapiens | Potency | = | 25118.9 | nM | PMID[521199] |
NPT568 | Individual Protein | Matrix metalloproteinase-2 | Homo sapiens | Inhibition | = | 43.0 | % | PMID[521203] |
NPT280 | Individual Protein | Matrix metalloproteinase 9 | Homo sapiens | Inhibition | = | 18.0 | % | PMID[521203] |
NPT569 | Individual Protein | Matrix metalloproteinase 8 | Homo sapiens | Inhibition | = | 47.0 | % | PMID[521203] |
NPT150 | Individual Protein | Anthrax lethal factor | Bacillus anthracis | Inhibition | = | 29.0 | % | PMID[521203] |
NPT270 | Individual Protein | Nitric oxide synthase, inducible | Mus musculus | Inhibition | = | 10.0 | % | PMID[521203] |
NPT570 | Individual Protein | Arachidonate 5-lipoxygenase | Homo sapiens | Inhibition | = | 23.0 | % | PMID[521203] |
NPT43 | Individual Protein | Tyrosinase | Agaricus bisporus | Inhibition | = | 75.0 | % | PMID[521203] |
NPT567 | Individual Protein | Matrix metalloproteinase 3 | Homo sapiens | Inhibition | = | 80.0 | % | PMID[521203] |
NPT152 | Individual Protein | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | Potency | n.a. | 20596.2 | nM | PMID[521204] |
NPT62 | Individual Protein | 6-phospho-1-fructokinase | Trypanosoma brucei | Potency | n.a. | 28183.8 | nM | PMID[521201] |
NPT5 | Individual Protein | Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 | Homo sapiens | Potency | n.a. | 22.4 | nM | PMID[521200] |
NPT5 | Individual Protein | Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 | Homo sapiens | Potency | n.a. | 5972.8 | nM | PMID[521204] |
NPT5 | Individual Protein | Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 | Homo sapiens | Potency | n.a. | 1122.0 | nM | PMID[521202] |
NPT63 | Individual Protein | Bromodomain adjacent to zinc finger domain protein 2B | Homo sapiens | Potency | n.a. | 3981.1 | nM | PMID[521202] |
NPT1139 | Individual Protein | Arachidonate 15-lipoxygenase, type II | Homo sapiens | Potency | n.a. | 19952.6 | nM | PMID[521199] |
NPT208 | Individual Protein | Cytochrome P450 1A2 | Homo sapiens | AC50 | = | 31622.78 | nM | PMID[521199] |
NPT109 | Individual Protein | Cytochrome P450 3A4 | Homo sapiens | AC50 | = | 25118.86 | nM | PMID[521199] |
NPT10 | Individual Protein | Geminin | Homo sapiens | Potency | n.a. | 33498.3 | nM | PMID[521201] |
NPT2808 | Individual Protein | Kelch-like ECH-associated protein 1 | Homo sapiens | Max_Activity_Concent | n.a. | 0.38 | uM | PMID[521202] |
NPT10 | Individual Protein | Geminin | Homo sapiens | Potency | n.a. | 2818.4 | nM | PMID[521202] |
NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | n.a. | 33498.3 | nM | PMID[521205] |
NPT71 | Cell Line | HEK293 | Homo sapiens | CC50 | > | 20000.0 | nM | PMID[521208] |
NPT2805 | Individual Protein | Dopamine beta-hydroxylase | Bos taurus | IC50 | = | 50.0 | nM | PMID[521209] |
NPT2805 | Individual Protein | Dopamine beta-hydroxylase | Bos taurus | Inhibition | = | 89.0 | % | PMID[521209] |
NPT2805 | Individual Protein | Dopamine beta-hydroxylase | Bos taurus | Inhibition | = | 92.0 | % | PMID[521209] |
NPT2805 | Individual Protein | Dopamine beta-hydroxylase | Bos taurus | Inhibition | = | 58.0 | % | PMID[521209] |
NPT2805 | Individual Protein | Dopamine beta-hydroxylase | Bos taurus | Inhibition | = | 20.0 | % | PMID[521209] |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | BP | > | 60.0 | mmHg | PMID[521189] |
NPT1016 | Organism | Canis familiaris | Canis lupus familiaris | MBP | = | -50.0 | n.a. | PMID[521189] |
NPT1016 | Organism | Canis familiaris | Canis lupus familiaris | HR | = | 32.0 | n.a. | PMID[521189] |
NPT1016 | Organism | Canis familiaris | Canis lupus familiaris | MBP | = | -45.0 | n.a. | PMID[521189] |
NPT1016 | Organism | Canis familiaris | Canis lupus familiaris | HR | = | 35.0 | n.a. | PMID[521189] |
NPT1016 | Organism | Canis familiaris | Canis lupus familiaris | MBP | = | -30.0 | n.a. | PMID[521189] |
NPT1016 | Organism | Canis familiaris | Canis lupus familiaris | HR | = | 33.0 | n.a. | PMID[521189] |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Level | = | 0.702 | ug of tissue | PMID[521190] |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Level | = | 6.55 | ug of tissue | PMID[521190] |
NPT2 | Others | Unspecified | Ratio | = | 0.109 | n.a. | PMID[521190] | |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Increase | = | 80.0 | % | PMID[521191] |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Decrease in blood pressure | = | 54.0 | mmHg | PMID[521191] |
NPT746 | Organism | Pasteurella multocida | Pasteurella multocida | MIC | = | 100.0 | ug.mL-1 | PMID[521196] |
NPT746 | Organism | Pasteurella multocida | Pasteurella multocida | MIC | = | 50.0 | ug.mL-1 | PMID[521196] |
NPT746 | Organism | Pasteurella multocida | Pasteurella multocida | Ratio | = | 2.0 | n.a. | PMID[521196] |
NPT197 | Protein-Protein Interaction | Menin/Histone-lysine N-methyltransferase MLL | Homo sapiens | Potency | = | 39810.7 | nM | PMID[521197] |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | Potency | = | 11220.2 | nM | PMID[521200] |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | Potency | = | 8912.5 | nM | PMID[521200] |
NPT794 | Individual Protein | Endonuclease 4 | Escherichia coli K-12 | Potency | = | 10000.0 | nM | PMID[521200] |
NPT94 | Individual Protein | Aldehyde dehydrogenase 1A1 | Homo sapiens | Potency | = | 501.2 | nM | PMID[521198] |
NPT94 | Individual Protein | Aldehyde dehydrogenase 1A1 | Homo sapiens | Potency | = | 3548.1 | nM | PMID[521200] |
NPT796 | Individual Protein | Peripheral myelin protein 22 | Homo sapiens | Potency | = | 60119.8 | nM | PMID[521201] |
NPT792 | Individual Protein | Arachidonate 15-lipoxygenase | Homo sapiens | Potency | = | 6309.6 | nM | PMID[521198] |
NPT792 | Individual Protein | Arachidonate 15-lipoxygenase | Homo sapiens | Potency | = | 15848.9 | nM | PMID[521199] |
NPT864 | Individual Protein | Lethal(3)malignant brain tumor-like protein 1 | Homo sapiens | Potency | = | 8912.5 | nM | PMID[521202] |
NPT95 | Individual Protein | Muscarinic acetylcholine receptor M1 | Rattus norvegicus | Potency | = | 141.3 | nM | PMID[521199] |
NPT96 | Individual Protein | Thrombopoietin | Homo sapiens | Potency | = | 1995.3 | nM | PMID[521199] |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | Potency | = | 14125.4 | nM | PMID[521200] |
NPT69 | Individual Protein | Matrix metalloproteinase-1 | Homo sapiens | Inhibition | = | 58.0 | % | PMID[521203] |
NPT533 | Protein-Protein Interaction | Runt-related transcription factor 1/Core-binding factor subunit beta | Homo sapiens | Potency | n.a. | 6309.6 | nM | PMID[521200] |
NPT533 | Protein-Protein Interaction | Runt-related transcription factor 1/Core-binding factor subunit beta | Homo sapiens | Potency | n.a. | 35481.3 | nM | PMID[521200] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | Potency | n.a. | 4775.5 | nM | PMID[521201] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | Potency | n.a. | 5221.3 | nM | PMID[521202] |
NPT98 | Individual Protein | HERG | Homo sapiens | Potency | n.a. | 5623.4 | nM | PMID[521200] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | Potency | n.a. | 18526.0 | nM | PMID[521202] |
NPT861 | Individual Protein | Isocitrate dehydrogenase [NADP] cytoplasmic | Homo sapiens | Potency | n.a. | 18356.4 | nM | PMID[521202] |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Activity | > | 60.0 | mmHg | PMID[521206] |
NPT1016 | Organism | Canis familiaris | Canis lupus familiaris | Activity | = | -50.0 | mmHg | PMID[521206] |
NPT1016 | Organism | Canis familiaris | Canis lupus familiaris | Activity | = | -45.0 | mmHg | PMID[521206] |
NPT1016 | Organism | Canis familiaris | Canis lupus familiaris | Activity | = | -30.0 | mmHg | PMID[521206] |
NPT1016 | Organism | Canis familiaris | Canis lupus familiaris | Activity | = | 32.0 | bpm | PMID[521206] |
NPT1016 | Organism | Canis familiaris | Canis lupus familiaris | Activity | = | 35.0 | bpm | PMID[521206] |
NPT1016 | Organism | Canis familiaris | Canis lupus familiaris | Activity | = | 33.0 | bpm | PMID[521206] |
NPT2809 | Organism | Squirrel monkey | Saimiri sciureus | Activity | = | -28.0 | mmHg | PMID[521206] |
NPT2809 | Organism | Squirrel monkey | Saimiri sciureus | Activity | = | -53.0 | mmHg | PMID[521206] |
NPT2809 | Organism | Squirrel monkey | Saimiri sciureus | Activity | = | -20.0 | bpm | PMID[521206] |
NPT2809 | Organism | Squirrel monkey | Saimiri sciureus | Activity | = | 10.0 | bpm | PMID[521206] |
NPT20 | Organism | Candida albicans | Candida albicans | MIC | > | 20000.0 | nM | PMID[521208] |
NPT85 | Organism | Filobasidiella neoformans | Cryptococcus neoformans | MIC | > | 20000.0 | nM | PMID[521208] |
NPT19 | Organism | Escherichia coli | Escherichia coli | MIC | > | 20000.0 | nM | PMID[521208] |
NPT173 | Organism | Klebsiella pneumoniae | Klebsiella pneumoniae | MIC | > | 20000.0 | nM | PMID[521208] |
NPT18 | Organism | Pseudomonas aeruginosa | Pseudomonas aeruginosa | MIC | > | 20000.0 | nM | PMID[521208] |
NPT747 | Organism | Acinetobacter baumannii | Acinetobacter baumannii | MIC | > | 20000.0 | nM | PMID[521208] |
NPT2922 | Organism | Staphylococcus aureus subsp. aureus | Staphylococcus aureus subsp. aureus | MIC | > | 20000.0 | nM | PMID[521208] |
NPT20950 | CELL-LINE | Erythrocyte | n.a. | HC10 | > | 20.0 | uM | PMID[521208] |
NPT2 | Others | Unspecified | Inhibition | = | 25.0 | % | PMID[521209] | |
NPT2 | Others | Unspecified | IC50 | = | 0.4 | ug/g | PMID[521209] | |
NPT2 | Others | Unspecified | IC50 | = | 0.1 | ug/g | PMID[521209] | |
NPT2 | Others | Unspecified | Potency | n.a. | 5353.8 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 10682.2 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 23710.1 | nM | PubChem BioAssay data set |
☑ Note for Activity Records:
☉ The quantitative biological activities were primarily integrated from ChEMBL (Version-30) database and were also directly collected from PubMed literature. PubMed PMID was provided as the reference link for each activity record.
Top-200 similar NPs were calculated against the active-NP-set (includes 4,3285 NPs with experimentally-derived bioactivity available in NPASS)
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC41717 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.9146 | High Similarity | NPC207851 |
0.9073 | High Similarity | NPC302159 |
0.8827 | High Similarity | NPC273532 |
0.8742 | High Similarity | NPC322644 |
0.8553 | High Similarity | NPC85443 |
0.8436 | Intermediate Similarity | NPC57398 |
0.8355 | Intermediate Similarity | NPC328029 |
0.8301 | Intermediate Similarity | NPC114310 |
0.8199 | Intermediate Similarity | NPC312860 |
0.8165 | Intermediate Similarity | NPC167400 |
0.8125 | Intermediate Similarity | NPC469489 |
0.8066 | Intermediate Similarity | NPC123395 |
0.8047 | Intermediate Similarity | NPC253810 |
0.8039 | Intermediate Similarity | NPC322488 |
0.8037 | Intermediate Similarity | NPC263455 |
0.8036 | Intermediate Similarity | NPC470894 |
0.8 | Intermediate Similarity | NPC29702 |
0.7927 | Intermediate Similarity | NPC33229 |
0.791 | Intermediate Similarity | NPC278434 |
0.7901 | Intermediate Similarity | NPC109922 |
0.7877 | Intermediate Similarity | NPC114974 |
0.7875 | Intermediate Similarity | NPC159630 |
0.7875 | Intermediate Similarity | NPC230085 |
0.7857 | Intermediate Similarity | NPC90229 |
0.7845 | Intermediate Similarity | NPC135950 |
0.7836 | Intermediate Similarity | NPC302647 |
0.7836 | Intermediate Similarity | NPC249614 |
0.7821 | Intermediate Similarity | NPC83111 |
0.7814 | Intermediate Similarity | NPC474916 |
0.7797 | Intermediate Similarity | NPC282103 |
0.7797 | Intermediate Similarity | NPC295158 |
0.779 | Intermediate Similarity | NPC230403 |
0.7772 | Intermediate Similarity | NPC103361 |
0.7758 | Intermediate Similarity | NPC107287 |
0.773 | Intermediate Similarity | NPC112741 |
0.7725 | Intermediate Similarity | NPC266249 |
0.7722 | Intermediate Similarity | NPC144381 |
0.7717 | Intermediate Similarity | NPC248782 |
0.7714 | Intermediate Similarity | NPC164340 |
0.7697 | Intermediate Similarity | NPC311282 |
0.7696 | Intermediate Similarity | NPC82370 |
0.7688 | Intermediate Similarity | NPC477976 |
0.7679 | Intermediate Similarity | NPC113812 |
0.7679 | Intermediate Similarity | NPC80681 |
0.7672 | Intermediate Similarity | NPC193238 |
0.7663 | Intermediate Similarity | NPC141454 |
0.7656 | Intermediate Similarity | NPC118940 |
0.7647 | Intermediate Similarity | NPC328596 |
0.7647 | Intermediate Similarity | NPC328318 |
0.7644 | Intermediate Similarity | NPC123839 |
0.7614 | Intermediate Similarity | NPC126709 |
0.7614 | Intermediate Similarity | NPC248041 |
0.7598 | Intermediate Similarity | NPC241025 |
0.7594 | Intermediate Similarity | NPC98864 |
0.7582 | Intermediate Similarity | NPC138370 |
0.7569 | Intermediate Similarity | NPC44354 |
0.7566 | Intermediate Similarity | NPC472259 |
0.7554 | Intermediate Similarity | NPC146724 |
0.7548 | Intermediate Similarity | NPC313823 |
0.7543 | Intermediate Similarity | NPC139763 |
0.7543 | Intermediate Similarity | NPC303225 |
0.7538 | Intermediate Similarity | NPC229893 |
0.7526 | Intermediate Similarity | NPC317373 |
0.7526 | Intermediate Similarity | NPC317752 |
0.7514 | Intermediate Similarity | NPC70949 |
0.7514 | Intermediate Similarity | NPC283219 |
0.75 | Intermediate Similarity | NPC267885 |
0.75 | Intermediate Similarity | NPC209362 |
0.7486 | Intermediate Similarity | NPC243058 |
0.7485 | Intermediate Similarity | NPC70406 |
0.7484 | Intermediate Similarity | NPC212125 |
0.7474 | Intermediate Similarity | NPC318299 |
0.7474 | Intermediate Similarity | NPC327592 |
0.7472 | Intermediate Similarity | NPC317010 |
0.7461 | Intermediate Similarity | NPC309845 |
0.7459 | Intermediate Similarity | NPC118084 |
0.7458 | Intermediate Similarity | NPC219848 |
0.7443 | Intermediate Similarity | NPC149155 |
0.7443 | Intermediate Similarity | NPC110500 |
0.7443 | Intermediate Similarity | NPC203468 |
0.744 | Intermediate Similarity | NPC251391 |
0.7421 | Intermediate Similarity | NPC165599 |
0.7416 | Intermediate Similarity | NPC256268 |
0.7414 | Intermediate Similarity | NPC78020 |
0.7405 | Intermediate Similarity | NPC324611 |
0.7405 | Intermediate Similarity | NPC256893 |
0.7401 | Intermediate Similarity | NPC476419 |
0.7401 | Intermediate Similarity | NPC84347 |
0.7394 | Intermediate Similarity | NPC467188 |
0.7387 | Intermediate Similarity | NPC54066 |
0.738 | Intermediate Similarity | NPC473814 |
0.738 | Intermediate Similarity | NPC78767 |
0.7377 | Intermediate Similarity | NPC209917 |
0.7374 | Intermediate Similarity | NPC471997 |
0.7374 | Intermediate Similarity | NPC325705 |
0.7374 | Intermediate Similarity | NPC52831 |
0.7372 | Intermediate Similarity | NPC471313 |
0.7372 | Intermediate Similarity | NPC471311 |
0.7371 | Intermediate Similarity | NPC473764 |
0.7371 | Intermediate Similarity | NPC314940 |
0.7366 | Intermediate Similarity | NPC93390 |
0.7366 | Intermediate Similarity | NPC202812 |
0.7363 | Intermediate Similarity | NPC194040 |
0.7363 | Intermediate Similarity | NPC90415 |
0.736 | Intermediate Similarity | NPC157583 |
0.736 | Intermediate Similarity | NPC14113 |
0.736 | Intermediate Similarity | NPC84827 |
0.736 | Intermediate Similarity | NPC111275 |
0.736 | Intermediate Similarity | NPC145885 |
0.7348 | Intermediate Similarity | NPC203635 |
0.7348 | Intermediate Similarity | NPC285923 |
0.7348 | Intermediate Similarity | NPC46895 |
0.7345 | Intermediate Similarity | NPC469938 |
0.734 | Intermediate Similarity | NPC472284 |
0.7321 | Intermediate Similarity | NPC313889 |
0.7312 | Intermediate Similarity | NPC473821 |
0.731 | Intermediate Similarity | NPC116573 |
0.731 | Intermediate Similarity | NPC213914 |
0.7305 | Intermediate Similarity | NPC257142 |
0.7305 | Intermediate Similarity | NPC105811 |
0.7287 | Intermediate Similarity | NPC74153 |
0.7283 | Intermediate Similarity | NPC183805 |
0.7283 | Intermediate Similarity | NPC75544 |
0.7278 | Intermediate Similarity | NPC472260 |
0.7278 | Intermediate Similarity | NPC217021 |
0.7278 | Intermediate Similarity | NPC61011 |
0.7278 | Intermediate Similarity | NPC470679 |
0.7273 | Intermediate Similarity | NPC36405 |
0.7263 | Intermediate Similarity | NPC45459 |
0.7263 | Intermediate Similarity | NPC315491 |
0.7262 | Intermediate Similarity | NPC123906 |
0.7261 | Intermediate Similarity | NPC165370 |
0.7261 | Intermediate Similarity | NPC306397 |
0.7241 | Intermediate Similarity | NPC265100 |
0.7236 | Intermediate Similarity | NPC472285 |
0.7234 | Intermediate Similarity | NPC77061 |
0.7229 | Intermediate Similarity | NPC471323 |
0.7228 | Intermediate Similarity | NPC206186 |
0.7225 | Intermediate Similarity | NPC471944 |
0.7222 | Intermediate Similarity | NPC55772 |
0.7222 | Intermediate Similarity | NPC237740 |
0.7222 | Intermediate Similarity | NPC213468 |
0.7219 | Intermediate Similarity | NPC473878 |
0.7216 | Intermediate Similarity | NPC244741 |
0.7212 | Intermediate Similarity | NPC182222 |
0.7211 | Intermediate Similarity | NPC81535 |
0.7207 | Intermediate Similarity | NPC150048 |
0.7207 | Intermediate Similarity | NPC203754 |
0.7202 | Intermediate Similarity | NPC473239 |
0.72 | Intermediate Similarity | NPC477975 |
0.7198 | Intermediate Similarity | NPC159125 |
0.7184 | Intermediate Similarity | NPC242116 |
0.7182 | Intermediate Similarity | NPC73994 |
0.7178 | Intermediate Similarity | NPC472288 |
0.7178 | Intermediate Similarity | NPC65408 |
0.7176 | Intermediate Similarity | NPC109158 |
0.7176 | Intermediate Similarity | NPC284348 |
0.7174 | Intermediate Similarity | NPC235684 |
0.7173 | Intermediate Similarity | NPC470279 |
0.7173 | Intermediate Similarity | NPC213308 |
0.7167 | Intermediate Similarity | NPC83774 |
0.7166 | Intermediate Similarity | NPC56170 |
0.7165 | Intermediate Similarity | NPC472287 |
0.7165 | Intermediate Similarity | NPC472286 |
0.7164 | Intermediate Similarity | NPC313804 |
0.7164 | Intermediate Similarity | NPC315804 |
0.7158 | Intermediate Similarity | NPC212213 |
0.7151 | Intermediate Similarity | NPC154339 |
0.715 | Intermediate Similarity | NPC27041 |
0.7143 | Intermediate Similarity | NPC472752 |
0.7135 | Intermediate Similarity | NPC36498 |
0.7135 | Intermediate Similarity | NPC252590 |
0.7128 | Intermediate Similarity | NPC267343 |
0.7128 | Intermediate Similarity | NPC45850 |
0.7128 | Intermediate Similarity | NPC321428 |
0.7127 | Intermediate Similarity | NPC219336 |
0.7126 | Intermediate Similarity | NPC131718 |
0.7125 | Intermediate Similarity | NPC315320 |
0.7121 | Intermediate Similarity | NPC111732 |
0.712 | Intermediate Similarity | NPC160127 |
0.712 | Intermediate Similarity | NPC50997 |
0.7114 | Intermediate Similarity | NPC314270 |
0.7107 | Intermediate Similarity | NPC471589 |
0.7105 | Intermediate Similarity | NPC106824 |
0.7104 | Intermediate Similarity | NPC48938 |
0.7101 | Intermediate Similarity | NPC100726 |
0.7093 | Intermediate Similarity | NPC63562 |
0.7091 | Intermediate Similarity | NPC43477 |
0.7085 | Intermediate Similarity | NPC236668 |
0.7085 | Intermediate Similarity | NPC89508 |
0.7081 | Intermediate Similarity | NPC315555 |
0.7079 | Intermediate Similarity | NPC74360 |
0.7077 | Intermediate Similarity | NPC82053 |
0.7076 | Intermediate Similarity | NPC153769 |
0.7072 | Intermediate Similarity | NPC183662 |
0.7072 | Intermediate Similarity | NPC217372 |
0.7072 | Intermediate Similarity | NPC15573 |
0.7072 | Intermediate Similarity | NPC237188 |
0.7062 | Intermediate Similarity | NPC114637 |
0.7059 | Intermediate Similarity | NPC13432 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC41717 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.8683 | High Similarity | NPD3178 | Discontinued |
0.8165 | Intermediate Similarity | NPD9074 | Approved |
0.8165 | Intermediate Similarity | NPD9075 | Approved |
0.815 | Intermediate Similarity | NPD1096 | Discontinued |
0.8086 | Intermediate Similarity | NPD180 | Clinical (unspecified phase) |
0.8072 | Intermediate Similarity | NPD5088 | Discontinued |
0.8045 | Intermediate Similarity | NPD5975 | Clinical (unspecified phase) |
0.8035 | Intermediate Similarity | NPD1783 | Clinical (unspecified phase) |
0.7964 | Intermediate Similarity | NPD1631 | Approved |
0.7911 | Intermediate Similarity | NPD107 | Approved |
0.7898 | Intermediate Similarity | NPD2896 | Discontinued |
0.7898 | Intermediate Similarity | NPD203 | Clinical (unspecified phase) |
0.7784 | Intermediate Similarity | NPD5255 | Approved |
0.7784 | Intermediate Similarity | NPD1630 | Approved |
0.7778 | Intermediate Similarity | NPD1573 | Approved |
0.7778 | Intermediate Similarity | NPD1575 | Approved |
0.773 | Intermediate Similarity | NPD9271 | Approved |
0.7714 | Intermediate Similarity | NPD8304 | Clinical (unspecified phase) |
0.7619 | Intermediate Similarity | NPD820 | Phase 3 |
0.7614 | Intermediate Similarity | NPD1587 | Approved |
0.7614 | Intermediate Similarity | NPD5398 | Clinical (unspecified phase) |
0.7604 | Intermediate Similarity | NPD3779 | Clinical (unspecified phase) |
0.759 | Intermediate Similarity | NPD5965 | Clinical (unspecified phase) |
0.7586 | Intermediate Similarity | NPD750 | Phase 2 |
0.758 | Intermediate Similarity | NPD1627 | Clinical (unspecified phase) |
0.7556 | Intermediate Similarity | NPD3315 | Phase 3 |
0.7546 | Intermediate Similarity | NPD751 | Clinical (unspecified phase) |
0.7541 | Intermediate Similarity | NPD6665 | Discontinued |
0.7531 | Intermediate Similarity | NPD4805 | Approved |
0.75 | Intermediate Similarity | NPD1568 | Clinical (unspecified phase) |
0.75 | Intermediate Similarity | NPD749 | Clinical (unspecified phase) |
0.7486 | Intermediate Similarity | NPD2336 | Approved |
0.7484 | Intermediate Similarity | NPD9284 | Approved |
0.7474 | Intermediate Similarity | NPD5901 | Discontinued |
0.7443 | Intermediate Similarity | NPD482 | Approved |
0.7443 | Intermediate Similarity | NPD1586 | Approved |
0.7432 | Intermediate Similarity | NPD3321 | Discontinued |
0.7429 | Intermediate Similarity | NPD485 | Clinical (unspecified phase) |
0.7427 | Intermediate Similarity | NPD2511 | Approved |
0.7421 | Intermediate Similarity | NPD2121 | Clinical (unspecified phase) |
0.7412 | Intermediate Similarity | NPD2581 | Approved |
0.7412 | Intermediate Similarity | NPD2582 | Approved |
0.7407 | Intermediate Similarity | NPD4804 | Approved |
0.7389 | Intermediate Similarity | NPD5728 | Clinical (unspecified phase) |
0.7374 | Intermediate Similarity | NPD9510 | Approved |
0.7348 | Intermediate Similarity | NPD721 | Approved |
0.7333 | Intermediate Similarity | NPD3813 | Approved |
0.7326 | Intermediate Similarity | NPD2307 | Discontinued |
0.7322 | Intermediate Similarity | NPD4948 | Discontinued |
0.7317 | Intermediate Similarity | NPD5020 | Approved |
0.7312 | Intermediate Similarity | NPD4528 | Approved |
0.7312 | Intermediate Similarity | NPD4526 | Approved |
0.7312 | Intermediate Similarity | NPD1173 | Approved |
0.7312 | Intermediate Similarity | NPD4529 | Approved |
0.7305 | Intermediate Similarity | NPD4703 | Approved |
0.7305 | Intermediate Similarity | NPD4702 | Approved |
0.7299 | Intermediate Similarity | NPD926 | Approved |
0.7299 | Intermediate Similarity | NPD925 | Approved |
0.7294 | Intermediate Similarity | NPD5257 | Clinical (unspecified phase) |
0.7294 | Intermediate Similarity | NPD2809 | Approved |
0.7284 | Intermediate Similarity | NPD9506 | Approved |
0.7273 | Intermediate Similarity | NPD3717 | Discontinued |
0.7263 | Intermediate Similarity | NPD484 | Approved |
0.7261 | Intermediate Similarity | NPD9080 | Approved |
0.7257 | Intermediate Similarity | NPD4554 | Clinical (unspecified phase) |
0.7256 | Intermediate Similarity | NPD1649 | Discontinued |
0.7247 | Intermediate Similarity | NPD4736 | Clinical (unspecified phase) |
0.7247 | Intermediate Similarity | NPD9690 | Approved |
0.7245 | Intermediate Similarity | NPD7927 | Clinical (unspecified phase) |
0.7243 | Intermediate Similarity | NPD1213 | Phase 3 |
0.7239 | Intermediate Similarity | NPD9076 | Clinical (unspecified phase) |
0.7229 | Intermediate Similarity | NPD1352 | Discontinued |
0.7225 | Intermediate Similarity | NPD112 | Approved |
0.7225 | Intermediate Similarity | NPD9705 | Discontinued |
0.7211 | Intermediate Similarity | NPD6137 | Clinical (unspecified phase) |
0.7207 | Intermediate Similarity | NPD5100 | Phase 3 |
0.7202 | Intermediate Similarity | NPD1270 | Approved |
0.7202 | Intermediate Similarity | NPD6323 | Clinical (unspecified phase) |
0.7198 | Intermediate Similarity | NPD2092 | Phase 2 |
0.7198 | Intermediate Similarity | NPD2095 | Phase 2 |
0.7198 | Intermediate Similarity | NPD2094 | Phase 2 |
0.7192 | Intermediate Similarity | NPD6753 | Phase 1 |
0.7192 | Intermediate Similarity | NPD6752 | Phase 1 |
0.7179 | Intermediate Similarity | NPD2509 | Approved |
0.7179 | Intermediate Similarity | NPD2510 | Approved |
0.7178 | Intermediate Similarity | NPD201 | Phase 2 |
0.7178 | Intermediate Similarity | NPD200 | Phase 2 |
0.7172 | Intermediate Similarity | NPD3794 | Approved |
0.7172 | Intermediate Similarity | NPD3795 | Approved |
0.7169 | Intermediate Similarity | NPD3525 | Discontinued |
0.7168 | Intermediate Similarity | NPD604 | Clinical (unspecified phase) |
0.7166 | Intermediate Similarity | NPD4376 | Phase 3 |
0.7165 | Intermediate Similarity | NPD7010 | Phase 3 |
0.716 | Intermediate Similarity | NPD272 | Approved |
0.7159 | Intermediate Similarity | NPD4174 | Clinical (unspecified phase) |
0.7158 | Intermediate Similarity | NPD2096 | Phase 2 |
0.7158 | Intermediate Similarity | NPD2091 | Phase 2 |
0.7157 | Intermediate Similarity | NPD5475 | Discontinued |
0.7151 | Intermediate Similarity | NPD158 | Discontinued |
0.7151 | Intermediate Similarity | NPD4883 | Approved |
0.7151 | Intermediate Similarity | NPD276 | Clinical (unspecified phase) |
0.715 | Intermediate Similarity | NPD3326 | Clinical (unspecified phase) |
0.7143 | Intermediate Similarity | NPD7061 | Clinical (unspecified phase) |
0.7135 | Intermediate Similarity | NPD6791 | Phase 2 |
0.7135 | Intermediate Similarity | NPD9364 | Phase 2 |
0.7135 | Intermediate Similarity | NPD9363 | Approved |
0.7129 | Intermediate Similarity | NPD5827 | Discontinued |
0.7125 | Intermediate Similarity | NPD9207 | Approved |
0.7125 | Intermediate Similarity | NPD9206 | Approved |
0.712 | Intermediate Similarity | NPD6999 | Discontinued |
0.712 | Intermediate Similarity | NPD7000 | Clinical (unspecified phase) |
0.7113 | Intermediate Similarity | NPD3947 | Discontinued |
0.711 | Intermediate Similarity | NPD4670 | Clinical (unspecified phase) |
0.711 | Intermediate Similarity | NPD4669 | Clinical (unspecified phase) |
0.711 | Intermediate Similarity | NPD4671 | Clinical (unspecified phase) |
0.71 | Intermediate Similarity | NPD3394 | Approved |
0.71 | Intermediate Similarity | NPD3389 | Approved |
0.71 | Intermediate Similarity | NPD3393 | Approved |
0.7088 | Intermediate Similarity | NPD6452 | Discontinued |
0.7085 | Intermediate Similarity | NPD3243 | Approved |
0.7076 | Intermediate Similarity | NPD9706 | Clinical (unspecified phase) |
0.7074 | Intermediate Similarity | NPD5505 | Discontinued |
0.7065 | Intermediate Similarity | NPD6178 | Phase 3 |
0.7062 | Intermediate Similarity | NPD425 | Approved |
0.7062 | Intermediate Similarity | NPD424 | Approved |
0.7062 | Intermediate Similarity | NPD5611 | Phase 2 |
0.7059 | Intermediate Similarity | NPD8356 | Approved |
0.7059 | Intermediate Similarity | NPD3575 | Approved |
0.7059 | Intermediate Similarity | NPD3576 | Approved |
0.7059 | Intermediate Similarity | NPD8063 | Discontinued |
0.7056 | Intermediate Similarity | NPD6529 | Discontinued |
0.7053 | Intermediate Similarity | NPD7818 | Clinical (unspecified phase) |
0.7052 | Intermediate Similarity | NPD1274 | Clinical (unspecified phase) |
0.7049 | Intermediate Similarity | NPD9362 | Approved |
0.7041 | Intermediate Similarity | NPD6838 | Clinical (unspecified phase) |
0.7039 | Intermediate Similarity | NPD8289 | Discontinued |
0.7027 | Intermediate Similarity | NPD4889 | Approved |
0.7026 | Intermediate Similarity | NPD4903 | Approved |
0.7026 | Intermediate Similarity | NPD944 | Approved |
0.7026 | Intermediate Similarity | NPD6987 | Phase 1 |
0.7026 | Intermediate Similarity | NPD4905 | Approved |
0.7026 | Intermediate Similarity | NPD4906 | Approved |
0.7024 | Intermediate Similarity | NPD3222 | Phase 2 |
0.7024 | Intermediate Similarity | NPD6173 | Approved |
0.7022 | Intermediate Similarity | NPD1343 | Approved |
0.7022 | Intermediate Similarity | NPD2781 | Approved |
0.702 | Intermediate Similarity | NPD7998 | Clinical (unspecified phase) |
0.7017 | Intermediate Similarity | NPD3238 | Discontinued |
0.7011 | Intermediate Similarity | NPD9383 | Approved |
0.7011 | Intermediate Similarity | NPD9382 | Approved |
0.7011 | Intermediate Similarity | NPD7401 | Clinical (unspecified phase) |
0.7006 | Intermediate Similarity | NPD2782 | Approved |
0.7006 | Intermediate Similarity | NPD2780 | Approved |
0.7005 | Intermediate Similarity | NPD7234 | Approved |
0.7005 | Intermediate Similarity | NPD7233 | Approved |
0.7 | Intermediate Similarity | NPD1095 | Clinical (unspecified phase) |
0.7 | Intermediate Similarity | NPD2077 | Approved |
0.7 | Intermediate Similarity | NPD2076 | Approved |
0.6995 | Remote Similarity | NPD1643 | Phase 3 |
0.6994 | Remote Similarity | NPD2061 | Approved |
0.699 | Remote Similarity | NPD4904 | Approved |
0.699 | Remote Similarity | NPD4862 | Clinical (unspecified phase) |
0.699 | Remote Similarity | NPD2317 | Clinical (unspecified phase) |
0.6989 | Remote Similarity | NPD5400 | Approved |
0.6985 | Remote Similarity | NPD7470 | Discontinued |
0.6984 | Remote Similarity | NPD981 | Phase 2 |
0.6978 | Remote Similarity | NPD2753 | Discontinued |
0.6977 | Remote Similarity | NPD6158 | Phase 2 |
0.6977 | Remote Similarity | NPD2882 | Phase 1 |
0.6977 | Remote Similarity | NPD6476 | Clinical (unspecified phase) |
0.6974 | Remote Similarity | NPD5513 | Phase 2 |
0.6965 | Remote Similarity | NPD7538 | Clinical (unspecified phase) |
0.6961 | Remote Similarity | NPD1996 | Discontinued |
0.6961 | Remote Similarity | NPD5322 | Clinical (unspecified phase) |
0.6961 | Remote Similarity | NPD5065 | Approved |
0.6961 | Remote Similarity | NPD3280 | Approved |
0.6959 | Remote Similarity | NPD5017 | Discontinued |
0.695 | Remote Similarity | NPD5866 | Approved |
0.6946 | Remote Similarity | NPD9599 | Approved |
0.6941 | Remote Similarity | NPD7469 | Discontinued |
0.6941 | Remote Similarity | NPD6148 | Clinical (unspecified phase) |
0.6932 | Remote Similarity | NPD9398 | Clinical (unspecified phase) |
0.6927 | Remote Similarity | NPD6872 | Clinical (unspecified phase) |
0.6927 | Remote Similarity | NPD5862 | Discovery |
0.6927 | Remote Similarity | NPD1292 | Clinical (unspecified phase) |
0.6927 | Remote Similarity | NPD2844 | Phase 3 |
0.6923 | Remote Similarity | NPD7187 | Phase 2 |
0.6923 | Remote Similarity | NPD8430 | Approved |
0.6912 | Remote Similarity | NPD7404 | Approved |
0.6911 | Remote Similarity | NPD4427 | Phase 2 |
0.6907 | Remote Similarity | NPD5043 | Discontinued |
0.6904 | Remote Similarity | NPD2715 | Clinical (unspecified phase) |
0.6904 | Remote Similarity | NPD7001 | Phase 3 |
0.69 | Remote Similarity | NPD4417 | Approved |
0.6898 | Remote Similarity | NPD5809 | Phase 3 |
0.6898 | Remote Similarity | NPD706 | Phase 1 |
0.6891 | Remote Similarity | NPD7204 | Clinical (unspecified phase) |
0.6891 | Remote Similarity | NPD4987 | Clinical (unspecified phase) |
0.6882 | Remote Similarity | NPD175 | Clinical (unspecified phase) |
0.6879 | Remote Similarity | NPD9343 | Clinical (unspecified phase) |
Bioactivity similarity was calculated based on bioactivity descriptors of compounds. The bioactivity descriptors were calculated by a recently developed AI algorithm Chemical Checker (CC) [Nature Biotechnology, 38:1087–1096, 2020; Nature Communications, 12:3932, 2021], which evaluated bioactivity similarities at five levels:
☉ A: chemistry similarity;
☉ B: biological targets similarity;
☉ C: networks similarity;
☉ D: cell-based bioactivity similarity;
☉ E: similarity based on clinical data.
Those 5 categories of CC bioactivity descriptors were calculated and then subjected to manifold projection using UMAP algorithm, to project all NPs on a 2-Dimensional space. The current NP was highlighted with a small circle in the 2-D map. Below figures: left-to-right, A-to-E.